Pegylated liposomal doxorubicin in ovarian cancer
Robert Strother1,2, Daniela Matei1–51Department of Medicine, 2Indiana University Melvin and Bren Simon Cancer Center, 3Department of Obstetrics and Gynecology, 4Department of Biochemistry and Molecular Biology, 5VA Roudebush Hospital Indiana University School of Medicine, 535 Barnhill...
Main Authors: | Robert Strother, Daniela Matei |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/tcrm-5148-pegylated-liposomal-doxorubicin-in-ovarian-a3432 |
Similar Items
-
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01) -
Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
by: Shushant Chib, et al.
Published: (2022-01-01) -
A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer
by: C. Forbes, et al.
Published: (2002-01-01) -
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
by: Robin L. Jones, et al.
Published: (2021-06-01) -
PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)